HDAC6 inhibitors unlocking CD20 expression on cancer cells

Unlocking Cancer Treatment: How HDAC6 Inhibitors Can Boost Immunotherapy

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 4 min read.

"New research reveals that inhibiting HDAC6 enhances the effectiveness of anti-CD20 monoclonal antibodies, offering a promising strategy to improve cancer immunotherapy."


Immunotherapy has revolutionized cancer treatment, but resistance remains a significant hurdle. One promising area of research focuses on improving the effectiveness of monoclonal antibodies, a key component of many immunotherapeutic regimens. A recent study published in 'Blood' sheds light on a novel approach to enhance the efficacy of anti-CD20 monoclonal antibodies, commonly used in treating B-cell lymphomas and leukemias.

The study, led by researchers from the Medical University of Warsaw, Poland, and collaborators from around the globe, explores the role of HDAC6 (histone deacetylase 6) inhibition in upregulating CD20 levels on cancer cells. CD20 is a protein found on the surface of B-cells, and it serves as a target for monoclonal antibodies like rituximab. By increasing CD20 levels, researchers aimed to make cancer cells more susceptible to antibody-mediated destruction.

This innovative research provides a compelling rationale for combining HDAC6 inhibitors with anti-CD20 monoclonal antibodies. As clinical trials continue and further research expands our understanding, this approach may soon offer a new and improved strategy for cancer immunotherapy.

AI Search Multiple angles on this topic

HDAC6: A Promising but Challenging Target

A September 1, 2024 review describes HDAC6 as an attractive target for anticancer drug discovery. It says conventional HDAC6 inhibitors have been hampered by limited clinical efficacy, acquired resistance, and an inability to inhibit HDAC6’s non-enzymatic functions. These limitations mean the target’s promise has not yet translated into a straightforward therapeutic solution.

Established Treatments Still Face Challenges

A September 29, 2026 review lists surgery, chemotherapy, radiotherapy, targeted therapy, endocrine therapy, and immunotherapy among approaches used in cancer treatment. It reports persistent challenges including drug resistance, recurrence, metastasis, and treatment-related toxicity. The review says these problems continue to compromise patient outcomes despite advances in treatment.

Why HDAC6 Inhibition Matters: Boosting CD20 Levels and Antibody Efficacy

HDAC6 inhibitors unlocking CD20 expression on cancer cells

The study's central finding revolves around the ability of HDAC6 inhibitors to increase CD20 levels on cancer cells. This is crucial because the amount of CD20 on a cell's surface directly impacts how well monoclonal antibodies can bind and trigger cell death. When CD20 levels are low, cancer cells become resistant to antibody therapy, diminishing its effectiveness. Researchers discovered that by inhibiting HDAC6, they could significantly increase CD20 expression, thereby resensitizing cancer cells to anti-CD20 monoclonal antibodies.

To validate their findings, the research team conducted a series of in vitro and in vivo experiments. These included:

  • In vitro studies: Using established B-cell tumor cell lines and primary malignant cells, researchers demonstrated that HDAC6 inhibition significantly increased CD20 levels. They used both pharmacological inhibitors and genetic approaches to confirm this effect.
  • CDC Assays: The researchers evaluated the impact of HDAC6 inhibition on complement-dependent cytotoxicity (CDC), a critical mechanism through which anti-CD20 antibodies kill cancer cells. The HDAC6 inhibitors significantly increased the efficacy of both rituximab and ofatumumab in CDC assays.
  • In vivo experiments: Mice treated with rituximab and an HDAC6 inhibitor showed improved survival compared to mice treated with rituximab alone. This provided further evidence that HDAC6 inhibition enhances the anti-tumor efficacy of anti-CD20 antibodies.
AI Search Multiple angles on this topic

AVS100 Boosts Immunotherapy in Preclinical Models

In the reported study, the HDAC6 inhibitor AVS100 (SS208) had antitumoral effects in SM1 melanoma and CT26 colon cancer models. It increased the efficacy of anti–programmed cell death protein 1 treatment in these models. The combination led to complete remission in the melanoma model and an increased response in the colon cancer model; these are model findings, not reported human outcomes.

Interpreting T-Cell Changes in CLL

A study examined HDAC6 silencing or inhibition in the Eμ-TCL1 model of chronic lymphocytic leukemia (CLL). When mice with similar tumor burdens were compared, the authors concluded that most observed T-cell changes were likely secondary to reduced tumor burden and immunomodulation of CLL B cells. This finding cautions against attributing those T-cell changes solely to a direct effect on T cells.

Clinical Responses in Two Different Studies

In the first-in-human study of the selective HDAC6 inhibitor KA2507 in patients with refractory solid tumors, stable disease was the best clinical response for 7 patients. In a separate phase II study of panobinostat plus rituximab in heavily pretreated diffuse large B-cell lymphoma, the overall response rate was 11% (90% CI [2%-34%]), with 2 subjects having a partial response. These results come from different drugs, patient groups, and studies, so they are not a head-to-head comparison.

The research team discovered that HDAC6 inhibition enhances CD20 protein synthesis without altering gene expression. This was a surprising finding, suggesting that HDAC6 plays a role in the post-transcriptional regulation of CD20. Further experiments revealed that HDAC6 inhibition increases the amount of CD20 mRNA associated with polysomes, the cellular machinery responsible for protein synthesis. This indicates that HDAC6 inhibition promotes the translation of CD20 mRNA into protein.

A Promising Future for HDAC6 Inhibitors in Cancer Therapy

The study's findings suggest that HDAC6 inhibition holds significant promise for improving cancer immunotherapy. By increasing CD20 levels and enhancing the efficacy of anti-CD20 monoclonal antibodies, this approach has the potential to overcome resistance and improve treatment outcomes for patients with B-cell lymphomas and leukemias. As clinical trials continue, the integration of HDAC6 inhibitors into cancer treatment regimens may represent a major step forward in the fight against cancer.

AI Search Multiple angles on this topic

Promise Alongside Prognostic Uncertainty

A report dated March 7, 2026 describes HDAC6 as a promising cancer therapeutic target because of its immunomodulatory effects. The same source says HDAC6’s prognostic significance remains debated. Its framing therefore pairs therapeutic interest with uncertainty about the prognostic evidence, rather than presenting HDAC6’s clinical value as settled.

HDAC6 and CD47 Checkpoint Blockade

A February 27, 2024 report describes a regulatory role for HDAC6 in phagocytosis and innate immunity. Its authors say their findings support investigating HDAC6 inhibitors to potentiate CD47 immune checkpoint blockade. The source presents this as a therapeutic strategy, not as evidence of established clinical benefit.

What the AVS100 Findings Show—and Do Not Show

The AVS100 (SS208) study reported antitumoral effects in SM1 melanoma and CT26 colon cancer models, with increased efficacy when combined with anti–programmed cell death protein 1 treatment. It reported complete remission in the melanoma model and an increased response in the colon cancer model. These findings concern cancer models; the provided source excerpt does not report patient outcomes.

How the combination compared with anti-PD-1 alone

  • 93% vs 61%; 10/13 vs 6/13In mice, 93% of tumors were responders with AVS100 plus anti-PD-1, compared with 61% with anti-PD-1 alone; complete remission occurred in 10 of 13 mice in the combination group versus 6 of 13 in the anti-PD-1 group.[1]

What the evidence says about HDAC6 and immune responses

The reported decrease in blood T-cell percentages with romidepsin shows that immune effects can differ across HDAC inhibitor classes. It does not by itself establish the effects of selective HDAC6 inhibition.[2]

How these findings fit with other immune-treatment evidence

In melanoma patient T cells, viability was not impaired at concentrations up to 1 μM with several tested inhibitors, including HDAC6-selective compounds; this is a cell-viability observation, not a measure of clinical efficacy.[3]

A review notes that evidence from solid-tumor patient studies of HDAC6 inhibition remains limited, with small treated groups contributing to inconclusive clinical results.[4]

The B16F10 melanoma model is described as less immunogenic and as having a lower mutational burden than human melanoma, which limits how directly its immune-checkpoint results can be generalized to patients.[5]

Separate work describes impaired tumor-infiltrating natural killer cells, including reduced activating markers and cytotoxic activity, as a challenge for immunotherapy; it frames better understanding of NK-cell biology as relevant context.[6]

What remains uncertain about HDAC6 and immunotherapy

  • Does the immune effect of HDAC6 inhibition translate into patient benefit in solid tumors, given the limited and inconclusive patient evidence described in the review?[4]
  • How do differences between the B16F10 model and human melanoma affect the relevance of immune-checkpoint findings across settings?[5]
  • How might the impaired features reported in tumor-infiltrating NK cells shape responses to immunotherapy, beyond the T-cell effects discussed elsewhere?[6]

Sources

  1. The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy (pmc.ncbi.nlm.nih.gov)
  2. HDAC inhibitors and immunotherapy; a double edged sword? (pmc.ncbi.nlm.nih.gov)
  3. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics (pmc.ncbi.nlm.nih.gov)
  4. Regulation of HDAC6 Catalytic Activity in Cancer: The Role of Post-Translational Modifications and Protein–Protein Interactions (pmc.ncbi.nlm.nih.gov)
  5. Targeting HDAC6 improves anti-CD47 immunotherapy (pmc.ncbi.nlm.nih.gov)
  6. HDAC6 orchestrates NK cell maturation and antitumor immunity (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is HDAC6 and why is inhibiting it relevant to cancer treatment?

HDAC6, or histone deacetylase 6, is an enzyme that plays a role in regulating the amount of CD20 protein on cancer cells. Inhibiting HDAC6 has been shown to increase CD20 levels, which is important because it makes cancer cells more vulnerable to destruction by monoclonal antibodies. This inhibition does not alter gene expression, but rather enhances CD20 protein synthesis.

2

What are anti-CD20 monoclonal antibodies and how are they used in cancer treatment?

Anti-CD20 monoclonal antibodies, such as rituximab, are a type of immunotherapy commonly used to treat B-cell lymphomas and leukemias. These antibodies target the CD20 protein found on the surface of B-cells, marking them for destruction. The effectiveness of these antibodies depends on the amount of CD20 present on the cancer cells. When CD20 levels are low, cancer cells become resistant to the therapy.

3

How does combining HDAC6 inhibitors with anti-CD20 monoclonal antibodies enhance cancer treatment?

The combination of HDAC6 inhibitors and anti-CD20 monoclonal antibodies works by increasing the amount of CD20 on cancer cells. HDAC6 inhibition boosts CD20 levels, making cancer cells more susceptible to the effects of anti-CD20 monoclonal antibodies like rituximab. This combined approach has the potential to overcome resistance to antibody therapy and improve treatment outcomes.

4

What kind of experiments were conducted to validate the effectiveness of HDAC6 inhibitors?

The researchers conducted in vitro studies using B-cell tumor cell lines, demonstrating that HDAC6 inhibition increased CD20 levels. They also performed CDC assays to show that HDAC6 inhibitors enhanced the efficacy of rituximab and ofatumumab. In vivo experiments in mice further validated these findings, showing that mice treated with both rituximab and an HDAC6 inhibitor had improved survival rates compared to those treated with rituximab alone.

5

Why is the strategy of using HDAC6 inhibitors to boost immunotherapy considered a promising approach?

This approach is significant because it offers a potential way to improve the effectiveness of cancer immunotherapy, specifically for B-cell lymphomas and leukemias. By increasing CD20 levels on cancer cells, HDAC6 inhibitors can resensitize resistant cells to anti-CD20 monoclonal antibodies. This could lead to better treatment outcomes and provide new hope for patients who have not responded well to existing therapies.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.